BioSpace News Archive

A spirit of urgency and collaboration broke down traditional informational barriers as industry and academia organized like never before in modern history to develop a vaccine in just nine months.

Adding Yervoy to the therapy did not improve overall survival (OS) or progression-free survival (PFS) but did add toxicity to Keytruda monotherapy.

The round was led by The Engine, a venture capital firm born at Massachusetts Institute of Technology, and Khosla Ventures and joined by Humboldt Fund and 8VC.

Gilead Sciences has inked a collaboration, option and license deal with Gritstone Oncology to create a vaccine-based immunotherapy as a cure for HIV.

Concert Pharmaceuticals said its Phase II clinical trial for its adjunctive schizophrenia treatment, CTP-692, did not meet the primary endpoint or other secondary endpoints, causing the company to halt development of the drug.

China’s Clover Biopharmaceuticals is spurning GlaxoSmithKline’s adjuvant vaccine technology in favor of one created by California-based Dynavax Technologies.

Shares of Viela Bio skyrocketed more than 52% in premarket trading after Ireland’s Horizon Therapeutics announced it was acquiring the company in a $3.05 billion deal.

Junshi receives upfront payment of $50 million for U.S. and Canadian rights to its immuno-oncology drug.

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), and Prevent Blindness, the nation’s oldest volunteer eye health non-profit organization, today announced they are joining together for the sixth consecutive year during AMD Awareness Month to raise awareness of Age-Related Macular Degeneration (AMD)

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced they have entered into an agreement to support the supply of Dynavax’s CpG 1018